Propylallyltryptamine
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Propylallyltryptamine (PALT), also known as N-propyl-N-allyltryptamine or by its developmental code name ASR-3004, is a serotonin receptor modulator of the tryptamine family.[1] It is an asymmetrical analogue of dipropyltryptamine (DPT) and diallyltryptamine (DALT).[1] The drug is a non-selective serotonin receptor agonist, including of the serotonin 5-HT1B, 5-HT2A, 5-HT2B, and 5-HT6 receptors, but not of the serotonin 5-HT1A receptor.[1] It is also a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI).[1] The chemical synthesis of PALT has been described.[1] A notable analogue of PALT is iPALT (ASR-3003).[1] PALT was patented by the Alexander Shulgin Research Institute (ASRI) in 2024.[1]
- None
| Clinical data | |
|---|---|
| Other names | PALT; N-Propyl-N-allyltryptamine; ASR-3004; ASR3004 |
| Drug class | Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C16H22N2 |
| Molar mass | 242.366 g·mol−1 |
| 3D model (JSmol) | |
| |
| |